ATDBIO LIMITED

Their core work

ATDbio is a Southampton-based SME specializing in custom oligonucleotide synthesis — the chemical manufacturing of short DNA and RNA sequences used in research, diagnostics, and therapeutics. Within H2020, they serve as an industry partner in Marie Skłodowska-Curie training networks, providing early-stage researchers with access to commercial-grade nucleic acid products and synthesis expertise. Their participation spans DNA nanotechnology, gene editing tools (CRISPR), and nucleic acid therapies, positioning them at the intersection of chemical manufacturing and life sciences R&D.

What they specialise in

How they've shifted over time

ATDbio's H2020 trajectory shows a clear progression from chemistry-driven gene therapy tools (ClickGene, 2015) toward structurally complex DNA nanotechnology (DNA-Robotics, 2018) and ultimately into therapeutic applications like CRISPR gene editing and immunotherapy (NATURE-ETN, 2020). The keyword data confirms this shift: recent projects are heavily loaded with application-oriented terms — immunotherapy, epigenetics, live cell imaging — rather than purely structural chemistry. This suggests the company is moving downstream from synthesis toward enabling next-generation therapies.

ATDbio is shifting from pure DNA synthesis toward application-ready nucleic acid products for gene editing and immunotherapy, making them increasingly relevant to therapeutic development consortia.

How they like to work

ATDbio participates exclusively as a partner, never as coordinator — consistent with their role as a specialist SME providing synthesis capabilities to academic-led training networks. With 29 unique partners across 11 countries from just 3 projects, they integrate into large, diverse consortia (MSCA-ITNs typically have 10-15 partners). This makes them an easy-to-work-with industry partner that brings commercial manufacturing know-how without seeking project leadership.

Despite only three projects, ATDbio has built a broad network of 29 partners across 11 countries, reflecting the large consortium structure of MSCA training networks. Their reach spans across Europe with no apparent geographic concentration beyond their UK base.

What sets them apart

ATDbio offers something rare in EU consortia: a commercial oligonucleotide manufacturer that actively participates in research training. Most DNA synthesis companies sell products but don't embed in research projects. For consortium builders, ATDbio brings both the ability to supply custom-designed nucleic acids and genuine industry context for training early-stage researchers — bridging the gap between academic discovery and commercial production.

Highlights from their portfolio

• NATURE-ETN
  Their largest-funded project (€303K) and most therapeutically ambitious, covering CRISPR, immunotherapy, and epigenetics — signaling ATDbio's move into high-impact application areas.
• DNA-Robotics
  Tackles DNA-based modular nanorobotics and biosensors, combining structural DNA nanotechnology with functional applications in an unusual and forward-looking topic.